Dilemma of Reporting Incidental Findings in Newborn Screening Programs for SCID: Parents’ Perspective on Ataxia Telangiectasia

Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an e...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 10; p. 2438
Main Authors Blom, Maartje, Schoenaker, Michiel H. D., Hulst, Myrthe, de Vries, Martine C., Weemaes, Corry M. R., Willemsen, Michèl A. A. P., Henneman, Lidewij, van der Burg, Mirjam
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 06.11.2019
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2019.02438

Cover

Abstract Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an early diagnosis of A-T at birth in a pre-symptomatic stage. While some countries embrace all incidental findings, the current policy in the Netherlands on reporting untreatable incidental findings is more conservative. We present parents' perspectives and considerations on the various advantages vs. disadvantages of early and late diagnosis of A-T. A questionnaire was developed and sent to 4,000 parents of healthy newborns who participated in the Dutch SONNET-study (implementation pilot for newborn screening for SCID). The questionnaire consisted of open-ended and scale questions on advantages and disadvantages of early and late diagnosis of A-T. To address potential bias, demographic characteristics of the study sample were compared to a reference population. A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis. Main arguments were to avoid a long period of uncertainty prior to diagnosis and to ensure the most optimal clinical care and guidance from the onset of symptoms. Parents who favored late diagnosis of A-T stated that early diagnosis would not lead to improved quality of life and preferred to enjoy the asymptomatic "golden years" with their child. The majority of parents (81.1%) stated that they would participate in newborn screening for A-T if a test was available. Reporting untreatable incidental findings remains a disputed topic worldwide. Although the current policy in the Netherlands is not to report untreatable incidental findings, unless the health advantage is clear, the majority of parents of healthy newborns are in favor of an early A-T diagnosis in the pre-symptomatic phase of the disorder. Our results as well as other studies that showed support for the screening of untreatable disorders may serve as valuable tools to inform policymakers in their considerations about NBS for untreatable disorders.
AbstractList Background: Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an early diagnosis of A-T at birth in a pre-symptomatic stage. While some countries embrace all incidental findings, the current policy in the Netherlands on reporting untreatable incidental findings is more conservative. We present parents' perspectives and considerations on the various advantages vs. disadvantages of early and late diagnosis of A-T.Methods: A questionnaire was developed and sent to 4,000 parents of healthy newborns who participated in the Dutch SONNET-study (implementation pilot for newborn screening for SCID). The questionnaire consisted of open-ended and scale questions on advantages and disadvantages of early and late diagnosis of A-T. To address potential bias, demographic characteristics of the study sample were compared to a reference population.Results: A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis. Main arguments were to avoid a long period of uncertainty prior to diagnosis and to ensure the most optimal clinical care and guidance from the onset of symptoms. Parents who favored late diagnosis of A-T stated that early diagnosis would not lead to improved quality of life and preferred to enjoy the asymptomatic “golden years” with their child. The majority of parents (81.1%) stated that they would participate in newborn screening for A-T if a test was available.Conclusions: Reporting untreatable incidental findings remains a disputed topic worldwide. Although the current policy in the Netherlands is not to report untreatable incidental findings, unless the health advantage is clear, the majority of parents of healthy newborns are in favor of an early A-T diagnosis in the pre-symptomatic phase of the disorder. Our results as well as other studies that showed support for the screening of untreatable disorders may serve as valuable tools to inform policymakers in their considerations about NBS for untreatable disorders.
Background: Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an early diagnosis of A-T at birth in a pre-symptomatic stage. While some countries embrace all incidental findings, the current policy in the Netherlands on reporting untreatable incidental findings is more conservative. We present parents' perspectives and considerations on the various advantages vs. disadvantages of early and late diagnosis of A-T. Methods: A questionnaire was developed and sent to 4,000 parents of healthy newborns who participated in the Dutch SONNET-study (implementation pilot for newborn screening for SCID). The questionnaire consisted of open-ended and scale questions on advantages and disadvantages of early and late diagnosis of A-T. To address potential bias, demographic characteristics of the study sample were compared to a reference population. Results: A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis. Main arguments were to avoid a long period of uncertainty prior to diagnosis and to ensure the most optimal clinical care and guidance from the onset of symptoms. Parents who favored late diagnosis of A-T stated that early diagnosis would not lead to improved quality of life and preferred to enjoy the asymptomatic "golden years" with their child. The majority of parents (81.1%) stated that they would participate in newborn screening for A-T if a test was available. Conclusions: Reporting untreatable incidental findings remains a disputed topic worldwide. Although the current policy in the Netherlands is not to report untreatable incidental findings, unless the health advantage is clear, the majority of parents of healthy newborns are in favor of an early A-T diagnosis in the pre-symptomatic phase of the disorder. Our results as well as other studies that showed support for the screening of untreatable disorders may serve as valuable tools to inform policymakers in their considerations about NBS for untreatable disorders.Background: Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an early diagnosis of A-T at birth in a pre-symptomatic stage. While some countries embrace all incidental findings, the current policy in the Netherlands on reporting untreatable incidental findings is more conservative. We present parents' perspectives and considerations on the various advantages vs. disadvantages of early and late diagnosis of A-T. Methods: A questionnaire was developed and sent to 4,000 parents of healthy newborns who participated in the Dutch SONNET-study (implementation pilot for newborn screening for SCID). The questionnaire consisted of open-ended and scale questions on advantages and disadvantages of early and late diagnosis of A-T. To address potential bias, demographic characteristics of the study sample were compared to a reference population. Results: A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis. Main arguments were to avoid a long period of uncertainty prior to diagnosis and to ensure the most optimal clinical care and guidance from the onset of symptoms. Parents who favored late diagnosis of A-T stated that early diagnosis would not lead to improved quality of life and preferred to enjoy the asymptomatic "golden years" with their child. The majority of parents (81.1%) stated that they would participate in newborn screening for A-T if a test was available. Conclusions: Reporting untreatable incidental findings remains a disputed topic worldwide. Although the current policy in the Netherlands is not to report untreatable incidental findings, unless the health advantage is clear, the majority of parents of healthy newborns are in favor of an early A-T diagnosis in the pre-symptomatic phase of the disorder. Our results as well as other studies that showed support for the screening of untreatable disorders may serve as valuable tools to inform policymakers in their considerations about NBS for untreatable disorders.
Background: Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an early diagnosis of A-T at birth in a pre-symptomatic stage. While some countries embrace all incidental findings, the current policy in the Netherlands on reporting untreatable incidental findings is more conservative. We present parents' perspectives and considerations on the various advantages vs. disadvantages of early and late diagnosis of A-T. Methods: A questionnaire was developed and sent to 4,000 parents of healthy newborns who participated in the Dutch SONNET-study (implementation pilot for newborn screening for SCID). The questionnaire consisted of open-ended and scale questions on advantages and disadvantages of early and late diagnosis of A-T. To address potential bias, demographic characteristics of the study sample were compared to a reference population. Results: A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis. Main arguments were to avoid a long period of uncertainty prior to diagnosis and to ensure the most optimal clinical care and guidance from the onset of symptoms. Parents who favored late diagnosis of A-T stated that early diagnosis would not lead to improved quality of life and preferred to enjoy the asymptomatic “golden years” with their child. The majority of parents (81.1%) stated that they would participate in newborn screening for A-T if a test was available. Conclusions: Reporting untreatable incidental findings remains a disputed topic worldwide. Although the current policy in the Netherlands is not to report untreatable incidental findings, unless the health advantage is clear, the majority of parents of healthy newborns are in favor of an early A-T diagnosis in the pre-symptomatic phase of the disorder. Our results as well as other studies that showed support for the screening of untreatable disorders may serve as valuable tools to inform policymakers in their considerations about NBS for untreatable disorders.
Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable immunodeficiency. A-T is one of the incidental findings that accompanies newborn screening (NBS) for severe combined immunodeficiency (SCID), leading to an early diagnosis of A-T at birth in a pre-symptomatic stage. While some countries embrace all incidental findings, the current policy in the Netherlands on reporting untreatable incidental findings is more conservative. We present parents' perspectives and considerations on the various advantages vs. disadvantages of early and late diagnosis of A-T. A questionnaire was developed and sent to 4,000 parents of healthy newborns who participated in the Dutch SONNET-study (implementation pilot for newborn screening for SCID). The questionnaire consisted of open-ended and scale questions on advantages and disadvantages of early and late diagnosis of A-T. To address potential bias, demographic characteristics of the study sample were compared to a reference population. A total of 664 of 4,000 parents sent back the questionnaire (response rate 16.6%). The vast majority of parents (81.9%) favored early diagnosis of A-T over late diagnosis. Main arguments were to avoid a long period of uncertainty prior to diagnosis and to ensure the most optimal clinical care and guidance from the onset of symptoms. Parents who favored late diagnosis of A-T stated that early diagnosis would not lead to improved quality of life and preferred to enjoy the asymptomatic "golden years" with their child. The majority of parents (81.1%) stated that they would participate in newborn screening for A-T if a test was available. Reporting untreatable incidental findings remains a disputed topic worldwide. Although the current policy in the Netherlands is not to report untreatable incidental findings, unless the health advantage is clear, the majority of parents of healthy newborns are in favor of an early A-T diagnosis in the pre-symptomatic phase of the disorder. Our results as well as other studies that showed support for the screening of untreatable disorders may serve as valuable tools to inform policymakers in their considerations about NBS for untreatable disorders.
Author de Vries, Martine C.
Weemaes, Corry M. R.
Henneman, Lidewij
Willemsen, Michèl A. A. P.
van der Burg, Mirjam
Hulst, Myrthe
Blom, Maartje
Schoenaker, Michiel H. D.
AuthorAffiliation 2 Department of Pediatric Neurology, Radboudumc Amalia Children's Hospital and Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center , Nijmegen , Netherlands
4 Department of Medical Ethics and Health Law, Leiden University Medical Center , Leiden , Netherlands
1 Department of Pediatrics, Leiden University Medical Centre , Leiden , Netherlands
6 Department of Clinical Genetics, Amsterdam Reproduction & Development Research Institute, Vrije Universiteit Amsterdam, Amsterdam UMC , Amsterdam , Netherlands
5 Department of Pediatrics, Radboudumc Amalia Children's Hospital, Radboud University Medical Center , Nijmegen , Netherlands
3 Department of Biologicals, Innovation and Screening, National Institute for Public Health and the Environment , Bilthoven , Netherlands
AuthorAffiliation_xml – name: 1 Department of Pediatrics, Leiden University Medical Centre , Leiden , Netherlands
– name: 3 Department of Biologicals, Innovation and Screening, National Institute for Public Health and the Environment , Bilthoven , Netherlands
– name: 4 Department of Medical Ethics and Health Law, Leiden University Medical Center , Leiden , Netherlands
– name: 6 Department of Clinical Genetics, Amsterdam Reproduction & Development Research Institute, Vrije Universiteit Amsterdam, Amsterdam UMC , Amsterdam , Netherlands
– name: 5 Department of Pediatrics, Radboudumc Amalia Children's Hospital, Radboud University Medical Center , Nijmegen , Netherlands
– name: 2 Department of Pediatric Neurology, Radboudumc Amalia Children's Hospital and Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center , Nijmegen , Netherlands
Author_xml – sequence: 1
  givenname: Maartje
  surname: Blom
  fullname: Blom, Maartje
– sequence: 2
  givenname: Michiel H. D.
  surname: Schoenaker
  fullname: Schoenaker, Michiel H. D.
– sequence: 3
  givenname: Myrthe
  surname: Hulst
  fullname: Hulst, Myrthe
– sequence: 4
  givenname: Martine C.
  surname: de Vries
  fullname: de Vries, Martine C.
– sequence: 5
  givenname: Corry M. R.
  surname: Weemaes
  fullname: Weemaes, Corry M. R.
– sequence: 6
  givenname: Michèl A. A. P.
  surname: Willemsen
  fullname: Willemsen, Michèl A. A. P.
– sequence: 7
  givenname: Lidewij
  surname: Henneman
  fullname: Henneman, Lidewij
– sequence: 8
  givenname: Mirjam
  surname: van der Burg
  fullname: van der Burg, Mirjam
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31781088$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1uEzEUhUeoiP7QPSvkJZsE_43HwwKpSilEqiCiZW3d8dwJrmbsYE9auutr8Ho8CU7SohYJb2xdn_NdXfscFns-eCyKV4xOhdD1284Nw3rKKaunlEuhnxUHTCk5EZzLvUfn_eI4pSual6yFEOWLYl-wSjOq9UFxd-p6HAYgoSNfcRXi6PySzL11LfoRenLmfJtLiThPPuNNE6InFzYi-o1wEcMywpBIFyK5mM1P35EFxOxMv-9-kQXGtEI7umskwZOTEX46IJfYg1-6XIfk4GXxvIM-4fH9flR8O_twOfs0Of_ycT47OZ9Yqfg4KTXUeVTkqFTeNJSqY2glb1hd6Q4AeN02NYIsK1BNrTpNq7JkteKqEp0WR8V8x20DXJlVdAPEWxPAmW0hxKWBPLzt0aAEDgoVNJWUrZK1LktBW-RtaS2WmFnvd6zVuhmwtXneCP0T6NMb776bZbg2SpeMsioD3twDYvixxjSawSWLfX4YDOtkuOBUVFpLlaWvH_f62-ThC7NA7QQ2hpQidsa6EUYXNq1dbxg1m7iYbVzMJi5mG5dspP8YH9j_tfwBJ0LGDg
CitedBy_id crossref_primary_10_1007_s12687_020_00488_y
crossref_primary_10_1016_j_jaci_2020_12_633
crossref_primary_10_1093_bmb_ldaa017
crossref_primary_10_3390_ijns8030040
crossref_primary_10_1111_dme_15131
crossref_primary_10_3389_fped_2021_706394
crossref_primary_10_3390_ijns9030051
crossref_primary_10_1007_s10875_020_00886_4
crossref_primary_10_1080_08820139_2020_1723104
crossref_primary_10_3390_genes11091018
crossref_primary_10_3389_fimmu_2021_686333
crossref_primary_10_1007_s12026_021_09216_1
crossref_primary_10_1080_14636778_2022_2091533
crossref_primary_10_1038_s41431_023_01469_8
crossref_primary_10_3390_ijns10020038
crossref_primary_10_1080_1744666X_2020_1810570
crossref_primary_10_1007_s11882_020_00955_z
crossref_primary_10_1097_MOP_0000000000001291
crossref_primary_10_3390_ijns9020022
Cites_doi 10.1016/j.jaci.2004.10.012
10.1111/cge.12710
10.1182/blood-2011-08-371021
10.1016/j.clim.2019.03.012
10.1093/jnci/djy028
10.1186/1750-1172-7-15
10.1016/j.srhc.2018.06.001
10.1007/s00431-019-03479-5
10.1002/mus.24100
10.1001/jama.2014.9132
10.1186/1471-2288-6-5
10.1007/s10875-016-0347-5
10.1111/dmcn.13424
10.1007/s10875-012-9846-1
10.1542/peds.2018-2300
10.1111/imr.12729
10.3389/fimmu.2017.01448
10.1186/s13023-016-0543-7
10.3390/ijns3020015
10.1159/000314644
10.1097/DBP.0b013e3181eedf01
10.1111/hex.12047
10.1111/j.1753-6405.2012.00854.x
10.1002/mgg3.353
ContentType Journal Article
Copyright Copyright © 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg.
Copyright © 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg. 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg
Copyright_xml – notice: Copyright © 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg.
– notice: Copyright © 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg. 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2019.02438
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ - The Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_e4a2a6e6ab744d64985530de2d5cce5e
PMC6851017
31781088
10_3389_fimmu_2019_02438
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c462t-58a9201e2e6601e8a56f1ec42b1978faaa29db9ea457a6b96f807551962673f83
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:19:06 EDT 2025
Thu Aug 21 18:22:54 EDT 2025
Fri Sep 05 11:07:41 EDT 2025
Thu Jan 02 22:58:50 EST 2025
Thu Apr 24 23:02:38 EDT 2025
Tue Jul 01 00:39:50 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords questionnaire
incidental finding
A-T
ataxia telangiectasia
parents' perspective
severe combined immunodeficiency
SCID
newborn screening
Language English
License Copyright © 2019 Blom, Schoenaker, Hulst, de Vries, Weemaes, Willemsen, Henneman and van der Burg.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-58a9201e2e6601e8a56f1ec42b1978faaa29db9ea457a6b96f807551962673f83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Jolan Eszter Walter, University of South Florida, United States
This article was submitted to Primary Immunodeficiencies, a section of the journal Frontiers in Immunology
Reviewed by: Anders Fasth, University of Gothenburg, Sweden; Nizar Mahlaoui, Necker-Enfants Malades Hospital, France
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2019.02438
PMID 31781088
PQID 2320378846
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_e4a2a6e6ab744d64985530de2d5cce5e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6851017
proquest_miscellaneous_2320378846
pubmed_primary_31781088
crossref_citationtrail_10_3389_fimmu_2019_02438
crossref_primary_10_3389_fimmu_2019_02438
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-11-06
PublicationDateYYYYMMDD 2019-11-06
PublicationDate_xml – month: 11
  year: 2019
  text: 2019-11-06
  day: 06
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2019
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References B20
B21
(B15) 2015
Amatuni (B3) 2019; 143
Wood (B24) 2014; 49
Chan (B4) 2005; 115
Dorsey (B7) 2017; 3
Boardman (B25) 2018; 6
Mallott (B13) 2013; 33
Puck (B8) 2019; 287
van Os (B10) 2017; 59
Weigelt (B12) 2018; 110
Schoenaker (B17) 2019
Borte (B14) 2012; 119
(B26) 2019
Kwan (B1) 2014; 312
Levy (B23) 2010; 31
B18
B19
van Os (B11) 2016; 90
Rechavi (B2) 2017; 8
Barbaro (B5) 2017; 37
Nakash (B30) 2006; 6
Weinreich (B16) 2012; 7
Morton (B29) 2012; 36
Hasegawa (B27) 2011; 14
Thomas (B6) 2019; 202
Wiklund (B22) 2018; 17
Hayeems (B28) 2015; 18
Rothblum-Oviatt (B9) 2016; 11
References_xml – volume: 115
  start-page: 391
  year: 2005
  ident: B4
  article-title: Development of population-based newborn screening for severe combined immunodeficiency
  publication-title: J Allergy Clin Immunol.
  doi: 10.1016/j.jaci.2004.10.012
– volume: 90
  start-page: 105
  year: 2016
  ident: B11
  article-title: Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline
  publication-title: Clin Genet.
  doi: 10.1111/cge.12710
– volume: 119
  start-page: 2552
  year: 2012
  ident: B14
  article-title: Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR
  publication-title: Blood.
  doi: 10.1182/blood-2011-08-371021
– ident: B20
– volume-title: Neonatal Screening for Spinal Muscular Atrophy.
  year: 2019
  ident: B26
– volume: 202
  start-page: 33
  year: 2019
  ident: B6
  article-title: Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results
  publication-title: Clin Immunol.
  doi: 10.1016/j.clim.2019.03.012
– volume: 110
  start-page: 1030
  year: 2018
  ident: B12
  article-title: The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers
  publication-title: J Natl Cancer Inst.
  doi: 10.1093/jnci/djy028
– ident: B21
– volume: 7
  start-page: 15
  year: 2012
  ident: B16
  article-title: Public support for neonatal screening for Pompe disease, a broad-phenotype condition
  publication-title: Orphanet J Rare Dis.
  doi: 10.1186/1750-1172-7-15
– ident: B18
– volume: 17
  start-page: 35
  year: 2018
  ident: B22
  article-title: New parents' experience of information and sense of security related to postnatal care: a systematic review
  publication-title: Sex Reprod Healthc.
  doi: 10.1016/j.srhc.2018.06.001
– year: 2019
  ident: B17
  article-title: Early diagnosis of Ataxia Telangiectasia in the neonatal phase: a parents' perspective
  doi: 10.1007/s00431-019-03479-5
– volume: 49
  start-page: 822
  year: 2014
  ident: B24
  article-title: Parental attitudes toward newborn screening for Duchenne/Becker muscular dystrophy and spinal muscular atrophy
  publication-title: Muscle Nerve.
  doi: 10.1002/mus.24100
– volume: 312
  start-page: 729
  year: 2014
  ident: B1
  article-title: Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States
  publication-title: JAMA.
  doi: 10.1001/jama.2014.9132
– volume: 6
  start-page: 5
  year: 2006
  ident: B30
  article-title: Maximising response to postal questionnaires–a systematic review of randomised trials in health research
  publication-title: BMC Med Res Methodol.
  doi: 10.1186/1471-2288-6-5
– volume: 37
  start-page: 51
  year: 2017
  ident: B5
  article-title: Newborn screening for severe primary immunodeficiency diseases in sweden-a 2-year pilot TREC and KREC screening study
  publication-title: J Clin Immunol.
  doi: 10.1007/s10875-016-0347-5
– volume-title: Neonatal Screening: New Recommendations.
  year: 2015
  ident: B15
– volume: 59
  start-page: 680
  year: 2017
  ident: B10
  article-title: Ataxia-telangiectasia: recommendations for multidisciplinary treatment
  publication-title: Dev Med Child Neurol.
  doi: 10.1111/dmcn.13424
– volume: 33
  start-page: 540
  year: 2013
  ident: B13
  article-title: Newborn screening for SCID identifies patients with ataxia telangiectasia
  publication-title: J Clin Immunol.
  doi: 10.1007/s10875-012-9846-1
– volume: 143
  start-page: e20182300
  year: 2019
  ident: B3
  article-title: Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California, 2010-2017
  publication-title: Pediatrics.
  doi: 10.1542/peds.2018-2300
– volume: 287
  start-page: 241
  year: 2019
  ident: B8
  article-title: Newborn screening for severe combined immunodeficiency and T-cell lymphopenia
  publication-title: Immunol Rev.
  doi: 10.1111/imr.12729
– volume: 8
  start-page: 1448
  year: 2017
  ident: B2
  article-title: First year of Israeli newborn screening for severe combined immunodeficiency-clinical achievements and insights
  publication-title: Front Immunol.
  doi: 10.3389/fimmu.2017.01448
– volume: 11
  start-page: 159
  year: 2016
  ident: B9
  article-title: Ataxia telangiectasia: a review
  publication-title: Orphan J Rare Dis.
  doi: 10.1186/s13023-016-0543-7
– volume: 3
  start-page: 15
  year: 2017
  ident: B7
  article-title: Newborn screening for severe combined immunodeficiency in the US: current status and approach to management
  publication-title: Int J Neonatal Screen.
  doi: 10.3390/ijns3020015
– volume: 14
  start-page: 298
  year: 2011
  ident: B27
  article-title: Parental attitudes toward ethical and social issues surrounding the expansion of newborn screening using new technologies
  publication-title: Public Health Genomics.
  doi: 10.1159/000314644
– volume: 31
  start-page: 622
  year: 2010
  ident: B23
  article-title: An overview of newborn screening
  publication-title: J Dev Behav Pediatr.
  doi: 10.1097/DBP.0b013e3181eedf01
– volume: 18
  start-page: 419
  year: 2015
  ident: B28
  article-title: Expectations and values about expanded newborn screening: a public engagement study
  publication-title: Health Expect.
  doi: 10.1111/hex.12047
– volume: 36
  start-page: 106
  year: 2012
  ident: B29
  article-title: In the 21st Century, what is an acceptable response rate?
  publication-title: Aust N Z J Public Health.
  doi: 10.1111/j.1753-6405.2012.00854.x
– ident: B19
– volume: 6
  start-page: 99
  year: 2018
  ident: B25
  article-title: Newborn genetic screening for spinal muscular atrophy in the UK: the views of the general population
  publication-title: Mol Genet Genomic Med.
  doi: 10.1002/mgg3.353
SSID ssj0000493335
Score 2.3396897
Snippet Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable...
Background: Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable...
Background: Ataxia Telangiectasia (A-T) is a severe DNA repair disorder that leads to a broad range of symptoms including neurodegeneration and a variable...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2438
SubjectTerms A-T
ataxia telangiectasia
Immunology
incidental finding
newborn screening
SCID
severe combined immunodeficiency
SummonAdditionalLinks – databaseName: DOAJ - The Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQSkhcEMuzvGQkLhxCE9txbW7LLtWCBKq0u9LeLMcZiyCaIppKy23_Bn-PX8KM3S0tQnDhmjiKMw_7m3jmG8aem1IE2veLqGMsFOi2aETtiyhlbAUIA0C1w-8_6OMz9e68Pt9q9UU5YZkeOAtuDMoLr0H7ZqJUq5U11OimBdHWIUANtPqWttwKpj5l3CulrPO5JEZhdhy7-XxFqVz2JZHwmZ19KNH1_wlj_p4qubX3TG-xm2vQyA_yZPfZNehvs-u5jeS3O-zyCF17Pvd8EXkG1LgfcfR8ahiK4JpPu1S7suRdz3FVQ7X3_CRQxg0NnOUUrSVH_MpPDt8eveIzKhEblj8uv_PZr2pMvuj5weAvOs9PgX50dnidqjDvsrPpm9PD42LdWaEISouhqI23KAoQoDEgA-NrHSsISjQVRpXRey9s21jwqp543VgdibMYwR6GPxMZjbzH9vpFDw8YV7psEJII35Ze6UrbEGUog4wVaQz0iI2v5OzCmnacul98dhh-kGZc0owjzbikmRF7sXniS6bc-MvY16S6zTgiy04X0ITc2oTcv0xoxJ5dKd6hc9GJie9hsVo6hJslEe4r_Iz72RA2r0LgZSq08hGb7JjIzlx27_Tdx0TgrU1aCR_-j8k_YjdIHKk8Uj9me8PXFTxBnDQ0T5NL_ATVbxVD
  priority: 102
  providerName: Directory of Open Access Journals
Title Dilemma of Reporting Incidental Findings in Newborn Screening Programs for SCID: Parents’ Perspective on Ataxia Telangiectasia
URI https://www.ncbi.nlm.nih.gov/pubmed/31781088
https://www.proquest.com/docview/2320378846
https://pubmed.ncbi.nlm.nih.gov/PMC6851017
https://doaj.org/article/e4a2a6e6ab744d64985530de2d5cce5e
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgCIkXxPfK2GQkJMRDtsRxXAdpmsZGGUigSlulvkWOc4agNWFNKm0v_O27c7KOogrxkofESWzfne939n0w9kaHwpLeD5xyLpCgiiAXiQlcHLtCgNAAFDv89Zs6mcgv02R6Gx7dT2Cz1rSjelKT-fnu5cXVAQr8PlmcqG_3XDmbLchLK92l_Hr6LrvnT4vIka8H-z87LBzHvuJmpJQMkJNld2659iMresqn81-HQf92pfxDN40esYc9qOSHHRc8ZnegesLud2Umr56y38co-rOZ4bXjHeBGfcVxZaCCojhuPip9bEvDy4rjqodsUfFTSx451HDcuXA1HPEtPz36fPyejymErG3e8vFtrCavK37YmsvS8DOgbdAS71OM5jM2GX08OzoJ-roLgZVKtEGiTYoTAQIUmmugTaJcBFaKPEKb0xljRFrkKRiZDI3KU-UoozFCQTSOhrHT8XO2UdUVbDIuVZgjYBGmCI1UkUqti21oYxeZfIicMWB7N7Oc2T4pOdXGOM_QOCG6ZJ4uGdEl83QZsHfLN351CTn-0fYDEW7ZjlJp-xv1_HvWS2YG0gijQFGHZKFkqqmSUgGiSKyFBAbs9Q3ZMxQ9Ok8xFdSLJkMwGlI6fonDeNGxwfJXCMt0hDIwYMMVBlnpy-qTqvzh03sr7dfJl__x3y32gEbrYyPVK7bRzhewjSCpzXf85gJeP02jHS8H14EaE4Q
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dilemma+of+Reporting+Incidental+Findings+in+Newborn+Screening+Programs+for+SCID%3A+Parents%27+Perspective+on+Ataxia+Telangiectasia&rft.jtitle=Frontiers+in+immunology&rft.au=Blom%2C+Maartje&rft.au=Schoenaker%2C+Michiel+H+D&rft.au=Hulst%2C+Myrthe&rft.au=de+Vries%2C+Martine+C&rft.date=2019-11-06&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=10&rft.spage=2438&rft_id=info:doi/10.3389%2Ffimmu.2019.02438&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon